Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GSACNASDAQ:JBIONASDAQ:SNGXNASDAQ:SNPX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSACGelStat$0.00-25.0%$0.00$0.00▼$0.00$1.50M3.1310.39 million shs952,777 shsJBIOJade Biosciences$9.89+5.1%$0.00$6.57▼$105.00$7.91M0.93367,116 shs2.14 million shsSNGXSoligenix$1.70-4.8%$1.93$1.68▼$14.83$5.83M1.97758,826 shs32,666 shsSNPXSynaptogenix$4.30+4.9%$2.70$1.84▼$5.52$5.70M1.08226,537 shs219,371 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSACGelStat-25.00%-25.00%-25.00%0.00%-25.00%JBIOJade Biosciences+5.10%+46.30%+988,999,900.00%+988,999,900.00%+988,999,900.00%SNGXSoligenix-4.49%-5.56%-9.57%-28.87%-59.91%SNPXSynaptogenix+4.88%+15.90%+89.85%+66.02%-2.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSACGelStatN/AN/AN/AN/AN/AN/AN/AN/AJBIOJade Biosciences2.564 of 5 stars3.50.00.00.03.11.70.6SNGXSoligenix0.4486 of 5 stars0.05.00.00.00.00.00.6SNPXSynaptogenix1.627 of 5 stars3.53.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSACGelStat 0.00N/AN/AN/AJBIOJade Biosciences 3.00Buy$14.0041.56% UpsideSNGXSoligenix 0.00N/AN/AN/ASNPXSynaptogenix 3.00Buy$14.00225.58% UpsideCurrent Analyst Ratings BreakdownLatest GSAC, SNPX, JBIO, and SNGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSACGelStatN/AN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ASNGXSoligenix-$117.03K-47.41N/AN/A$1.64 per share1.04SNPXSynaptogenixN/AN/AN/AN/A$4.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSACGelStatN/AN/A0.00∞N/AN/AN/AN/AN/AJBIOJade Biosciences-$69.63M-$59.650.00∞N/AN/A-60.01%-54.32%N/ASNGXSoligenix-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)SNPXSynaptogenix-$12.77M-$10.08N/A∞N/AN/A-115.28%-58.31%N/ALatest GSAC, SNPX, JBIO, and SNGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SNPXSynaptogenixN/A$0.04N/A$0.04N/AN/A5/9/2025Q1 2025SNGXSoligenix-$0.67-$1.06-$0.39-$1.06N/AN/A3/27/2025Q4 2024SNPXSynaptogenix-$2.06-$4.36-$2.30-$4.36N/AN/A3/21/2025Q4 2024SNGXSoligenix-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSACGelStatN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSACGelStatN/AN/AN/AJBIOJade BiosciencesN/A32.0132.01SNGXSoligenixN/A1.851.85SNPXSynaptogenixN/A72.5972.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSACGelStatN/AJBIOJade BiosciencesN/ASNGXSoligenix3.60%SNPXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipGSACGelStat20.50%JBIOJade Biosciences24.90%SNGXSoligenix3.05%SNPXSynaptogenix2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSACGelStat23.74 billion2.97 billionNot OptionableJBIOJade Biosciences20840,000632,000N/ASNGXSoligenix203.26 million3.16 millionNot OptionableSNPXSynaptogenix41.39 million1.35 millionNot OptionableGSAC, SNPX, JBIO, and SNGX HeadlinesRecent News About These CompaniesSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024August 16, 2024 | investorplace.comSynaptogenix Partners With LSU Health New Orleans To Study PUFA Analogs To Treat Spinal Cord InjuryJuly 19, 2024 | markets.businessinsider.comSynaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryJuly 18, 2024 | prnewswire.comSynaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisJune 26, 2024 | prnewswire.comSNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024May 20, 2024 | investorplace.comSynaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryMay 7, 2024 | prnewswire.comSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | finanznachrichten.deSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingApril 24, 2024 | prnewswire.comSynaptogenix announces reverse stock split to regain Nasdaq complianceApril 5, 2024 | uk.investing.comWhat's Going On With Synaptogenix (SNPX) Stock?April 4, 2024 | msn.comSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingApril 3, 2024 | finance.yahoo.comU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%February 22, 2024 | msn.comSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersDecember 19, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSAC, SNPX, JBIO, and SNGX Company DescriptionsGelStat OTCMKTS:GSAC$0.0003 0.00 (-25.00%) As of 06/20/2025 03:51 PM EasternGelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.Jade Biosciences NASDAQ:JBIO$9.89 +0.48 (+5.10%) As of 06/20/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Soligenix NASDAQ:SNGX$1.70 -0.09 (-4.76%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.76 +0.06 (+3.82%) As of 06/20/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Synaptogenix NASDAQ:SNPX$4.30 +0.20 (+4.88%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.22 -0.09 (-1.98%) As of 06/20/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
